Two new papers from scientists in the Nuffield Department of Medicine and other University of Oxford institutions have shown how the immune system reacts differently depending on the length of interval between vaccine doses.
In a collaborative new study, researchers have developed the first mathematically supported cellular map of lung tissue in idiopathic pulmonary fibrosis and uncovered key immune cell interactions that could explain why lungs fail to repair in this deadly disease with no known cure.
A new study from scientists at the Radcliffe Department of Medicine and Harvard Medical School, and funded by the British Heart Foundation, has uncovered a potential new treatment for hypertrophic cardiomyopathy (HCM).
The 2026 European Phagocyte Workshop will take place in the historic city of Oxford, UK, 23 \u2013 25 March 2026. This popular conference series highlights the latest advances in phagocyte biology. With capacity to host up to 250 delegates, we will bring together researchers from across the globe, providing plenty of networking opportunities to encourage new connections and collaborations.
The Thanks for the Memories public engagement programme are delighted to announce the next major event of their project: the premier of a new opera, \u2018Dangerous Matter\u2019, at the Royal Northern College of Music on June 24th, 2025, inspired by the story of Lady Mary Wortley Montagu and University of Oxford research into immune memory.
Researchers in the Nuffield Department of Medicine have found structures of immune cells in the gut that may be driving the response to gluten in people with coeliac disease. These findings could provide a target for future therapies.
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between cancerous and healthy tissues\u2014addressing a major challenge in current immunotherapy.
A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
The 2025 prize was awarded to Sooraj Achar (NCI/Kennedy Institute) for his outstanding contribution to understanding T cell antigen recognition, particularly in the context of cancer immunotherapy, and wider contributions to the immunology community.
Dr Kirsty McHugh and Dr Carolyn Nielsen discuss a recent Cell article: \u2018Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype\u2019.
The University of Oxford in partnership with the Coler Lab at Seattle Children\u2019s Research Institute (SCRI) has begun a new clinical trial called TB045, which aims to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-human aerosol mycobacterial challenge infection model with healthy adult volunteers.
In a recent study, researchers at the KEMRI Wellcome Trust Research Programme in Kenya have discovered that a low-dose of the yellow fever vaccine is as effective as the current standard dose.
Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded \u00a35 million to a group of interdisciplinary researchers from NDM and other departments at the University, to develop new therapies for drug-resistant tuberculosis.
After more than a year of community engagement and preparation in 100 villages with over 12,000 inhabitants across the Chittagong Hill Tracts, a mass malaria vaccine (R21/Matrix M) and drug administration (DHA, piperaquine, and single low dose primaquine) study was launched on 15 February.
![\"\"](\"https://www.immunology.ox.ac.uk/news/new-research-reveals-optimal-time-intervals-for-covid-19-vaccine-boosters/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n